Mirum Pharmaceuticals (NASDAQ:MIRM) Given “Market Outperform” Rating at Citizens Jmp

Citizens Jmp reissued their market outperform rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report report published on Tuesday,Benzinga reports. They currently have a $132.00 price target on the stock.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, March 23rd. Evercore set a $126.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Stifel Nicolaus lifted their target price on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $117.67.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $93.33 on Tuesday. Mirum Pharmaceuticals has a 1 year low of $38.33 and a 1 year high of $109.28. The firm has a 50 day moving average of $95.10 and a 200-day moving average of $84.38. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $5.63 billion, a P/E ratio of -194.43 and a beta of 0.51.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. During the same quarter last year, the firm posted $1.00 EPS. The business’s revenue was up 49.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.77 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joanne Quan sold 7,287 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This trade represents a 27.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Christopher Peetz sold 40,985 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the sale, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $17,872,541.82. This represents a 17.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 115,031 shares of company stock valued at $10,792,789 over the last quarter. Company insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of MIRM. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $30,000. MCF Advisors LLC grew its holdings in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the period. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth $32,000. CIBC Private Wealth Group LLC acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth $32,000. Finally, Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter worth $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.